Suven Life Sciences Limited has informed the Exchange regarding Outcome of Board Meeting held on March 06, 2026 on ALLOTMENT OF 3,17,68,764 EQUITY SHARES OF THE COMPANY ON PREFERENTIAL BASIS
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.3 pts more than Nifty Microcap 250 and 1.0 pts more than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Suven Life Sciences has allotted 3,17,68,764 equity shares of Rs. 1 each at Rs. 134 per share to Jasti Property and Equity Holdings Private Limited (trustee of Jasti Family Trust), a promoter group entity. The shares were issued on conversion of an equal number of fully paid warrants, with 100% consideration of Rs. 425.70 crore already received by the company. As a result, the paid-up equity capital has risen from Rs. 23.19 crore (23,19,51,819 shares) to Rs. 26.37 crore (26,37,20,583 shares), an increase of about 13.7% in share count. The allotment was done under the preferential route as per SEBI ICDR Regulations.
This is a promoter-driven capital infusion via warrant conversion, which signals confidence from the promoter group but also results in dilution of around 13.7% for existing non-promoter shareholders. The company has already received the full Rs. 425.70 crore, so there is no funding uncertainty. Share price may see mild pressure due to the dilution, though promoter strengthening is generally viewed positively.